Biotech startups that raised Series B in DACH
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| NovaGo Therapeutics | Schlieren | Series B | $29.7M | 2026-08-31 |
| Computomics | Tübingen | Series B | $7.3M | 2026-08-18 |
| Vaderis Therapeutics | Basel | Series B | $152.0M | 2026-08-11 |
| NVision Quantum Technologies | Ulm | Series B | $38.0M | 2026-05-13 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| Orbem | Munich | Series B | $64.6M | 2026-01-20 |
| Exciva | Heidelberg | Series B | $59.4M | 2026-01-20 |
| GlycoEra | Wädenswil | Series B | $130.0M | 2025-05-27 |
8 rows of the CSV in 5 of its 18 columns.
- The 67 biotech startups in DACH whose last round is Series B have raised $2.2B in total.
- 8 of them closed their most recent round in the last 12 months, $566.0M combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is NovaGo Therapeutics' $29.7M Series B on 31 August 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 15 of them, more than any other fund.
- Health care is the most common other sector, with 53 companies (79%).
- 6% were founded in 2020 or later; the median founding year is 2011.
- The most common team size is 11 to 50 employees (46% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
29 of 67| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen, Germany | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil, Switzerland | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| Clinomic | Clinomic is a medical AI company focused on critical care. | Artificial intelligence | Aachen, Germany | Series B | $25.3M | 2025-04-08 | $54.6M | German Federal Ministry of Research, Technology and Space | 51 to 100 | 2019 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel, Switzerland | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| Qualifyze | Qualifyze provides global quality audit and site risk management solutions for life sciences companies. | Biotech | Frankfurt, Germany | Series B | $54.0M | 2024-09-10 | Insight Partners, APX, HV Capital +2 | 101 to 250 | 2019 | |
| CorFlow Therapeutics | CorFlow Therapeutics develops proprietary technologies to diagnose and treat microvascular obstructions. | Biotech | Baar, Switzerland | Series B | $48.5M | 2024-09-10 | $66.1M | Innosuisse, Unorthodox Ventures, Panakes Partners +2 | 11 to 50 | 2016 |
| iOnctura | iOnctura is a clinical-stage biotechnology company developing treatments for cancer. | Biotech | Geneva, Switzerland | Series B | $85.7M | 2024-06-20 | European Innovation Council, M Ventures, VI Partners +2 | 11 to 50 | 2017 | |
| Hemotune | Hemotune develops a therapeutic blood purification platform for treating health conditions. | Biotech | Schlieren, Switzerland | Series B | $15.6M | 2024-03-25 | Venture Kick, Innosuisse, Gebert Rüf Stiftung | 11 to 50 | 2016 | |
| Resolve BioSciences | Resolve BioSciences conducts biotechnology research in molecular cartography. | Biotech | Düsseldorf, Germany | Series B | $71.0M | 2022-10-24 | $95.0M | HTGF (High-Tech Gruenderfonds), EDBI, NRW.BANK +2 | 51 to 100 | 2020 |
| Cardior Pharmaceuticals | Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. | Biotech | Hanover, Germany | Series B | $75.3M | 2021-08-25 | HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 | 11 to 50 | 2016 | |
| Topas Therapeutics | Topas Therapeutics is a biotechnology company developing products for major unmet medical needs. | Biotech | Hamburg, Germany | Series B | $21.4M | 2021-07-29 | Boehringer Ingelheim Venture Fund, BioMedPartners, Vesalius Biocapital Partners +1 | 51 to 100 | 2006 | |
| MaxiVAX | MaxiVAX is a Swiss clinical-stage biotechnology company. | Biotech | Geneva, Switzerland | Series B | $5.0M | 2019-11-27 | EIC Accelerator | 1 to 10 | 2005 | |
| Hemovent | Hemovent is an emerging medical device company developing new technology. | Biotech | Aachen, Germany | Series B | $5.2M | 2019-02-14 | $13.5M | KfW, NRW.BANK, TechVision Fund +2 | 1 to 10 | 2013 |
| Amal Therapeutics | Amal Therapeutics SA is a privately held Swiss and German biotech startup spun off from the University of Geneva. | Biotech | Geneva, Switzerland | Series B | $32.6M | 2018-11-12 | HTGF (High-Tech Gruenderfonds), Venture Kick, VI Partners +2 | 11 to 50 | 2012 | |
| Therachon | Therachon is a global biotechnology company developing medicines for rare genetic diseases. | Biotech | Basel, Switzerland | Series B | $60.0M | 2018-08-09 | $100.0M | Bpifrance, New Enterprise Associates, OrbiMed +2 | 1 to 10 | 2014 |
| Cardiorentis | Cardiorentis is a privately owned biopharmaceutical company. | Biotech | Zug, Switzerland | Series B | $60.4M | 2016-01-10 | HealthCare Royalty Partners | 1 to 10 | 2010 | |
| Covagen | Covagen develops protein-based therapeutics for inflammatory diseases and cancer. | Biotech | Schlieren, Switzerland | Series B | $66.1M | 2013-12-09 | Ventech, Novartis Venture Fund, Andera Partners +2 | 11 to 50 | 2007 | |
| Mind-NRG | Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases. | Biotech | Geneva, Switzerland | Series B | $7.9M | 2013-09-04 | Index Ventures, Limburgse Reconversie Maatschappij | 1 to 10 | 2010 | |
| Subitec | Subitec produces microalgae biomass substances for the cosmetics and food additives industries. | Biotech | Stuttgart, Germany | Series B | $5.5M | 2012-07-16 | HTGF (High-Tech Gruenderfonds), KfW, eCAPITAL ENTREPRENEURIAL PARTNERS +1 | 11 to 50 | 2000 | |
| Okairos | Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. | Biotech | Basel, Switzerland | Series B | $20.5M | 2010-09-14 | $30.1M | EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 | 1 to 10 | 2007 |
| ESBATech | ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. | Biotech | Schlieren, Switzerland | Series B | $22.0M | 2008-08-07 | Novartis Venture Fund, VI Partners, SV Health Investors +2 | 51 to 100 | 1998 | |
| Vivendy Therapeutics | Vivendy Therapeutics develops enzyme replacement therapies. | Biotech | Basel, Switzerland | Series B | $30.5M | 2008-06-23 | EQT Life Sciences, BioMedPartners, TVM Capital +1 | 11 to 50 | 2006 | |
| PregLem | PregLem is a Swiss biopharmaceutical company that develops and commercializes new drugs. | Biotech | Geneva, Switzerland | Series B | $32.2M | 2007-12-04 | $58.2M | Sofinnova Partners, Sofinnova Investments, MVM Life Science Partners +1 | 11 to 50 | 2006 |
Table 1. Biotech startups that raised Series B in DACH: the 29 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 67.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 3 | Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| 4 | Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 5 | NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| 6 | NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| 7 | Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen, Germany | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
Table 2. Biotech startups that raised Series B in DACH: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 15 | 22% | 1 | Computomics |
| 2 | Andera Partners | Private equity firm | Paris, France | 5 | 7% | 1 | Exciva |
| 3 | Venture Kick | Startup incubator | Schlieren, Switzerland | 4 | 6% | ||
| 4 | VI Partners | Venture capital firm | Altendorf, Switzerland | 4 | 6% | ||
| 5 | NRW.BANK | Government investment office | Düsseldorf, Germany | 4 | 6% | ||
| 6 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 4 | 6% | ||
| 7 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 4 | 6% | ||
| 8 | BioMedPartners | Venture capital firm | Basel, Switzerland | 4 | 6% | ||
| 9 | European Innovation Council | Startup accelerator | Brussels, Belgium | 3 | 4% | 2 | Computomics, Orbem |
| 10 | German Federal Ministry of Research, Technology and Space | Government investment office | Bonn, Germany | 3 | 4% | 1 | NVision Quantum Technologies |
| 11 | Sofinnova Partners | Venture capital firm | Paris, France | 3 | 4% | ||
| 12 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 3 | 4% | ||
| 13 | Innosuisse | Government investment office | Berne, Switzerland | 3 | 4% | ||
| 14 | Versant Ventures | Venture capital firm | Menlo Park, United States | 3 | 4% | ||
| 15 | KfW | Government investment office | Frankfurt, Germany | 3 | 4% |
Table 3. Biotech startups that raised Series B in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 53 | 79% | $2.1B |
| Software | 6 | 9% | $175.5M |
| Artificial intelligence | 3 | 4% | $171.2M |
| Hardware | 1 | 1% | $106.5M |
| Education | 1 | 1% |
Table 4. Biotech startups that raised Series B in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 67 | 100% | $21.4M |
Table 5. Biotech startups that raised Series B in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Germany | 35 | 52% |
| Switzerland | 31 | 46% |
| Austria | 1 | 1% |
Table 6. Biotech startups that raised Series B in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Basel | 7 | 10% |
| Munich | 5 | 7% |
| Geneva | 5 | 7% |
| Schlieren | 4 | 6% |
| Lausanne | 3 | 4% |
| Heidelberg | 2 | 3% |
| Aachen | 2 | 3% |
| Martinsried | 2 | 3% |
| Berlin | 2 | 3% |
| Bielefeld | 2 | 3% |
| Zug | 2 | 3% |
| Tübingen | 1 | 1% |
Table 7. Biotech startups that raised Series B in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 3 | 38% | $189.0M |
| June 2026 | 1 | 12% | $50.0M |
| May 2026 | 2 | 25% | $203.0M |
| January 2026 | 2 | 25% | $124.1M |
Table 8. Biotech startups that raised Series B in DACH: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 8 | 12% | $566.0M |
| 2025 | 4 | 6% | $231.3M |
| 2024 | 6 | 9% | $370.5M |
| 2023 | 1 | 1% | $11.0M |
| 2022 | 3 | 4% | $86.3M |
| 2021 | 6 | 9% | $285.7M |
Table 9. Biotech startups that raised Series B in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 1% |
| 2020 to 2022 | 3 | 4% |
| 2015 to 2019 | 19 | 28% |
| 2010 to 2014 | 17 | 25% |
| Before 2010 | 27 | 40% |
Table 10. Biotech startups that raised Series B in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 19 | 28% |
| 11 to 50 | 31 | 46% |
| 51 to 100 | 10 | 15% |
| 101 to 250 | 5 | 7% |
| 1,001 to 5,000 | 1 | 1% |
| 10,001 or more | 1 | 1% |
Table 11. Biotech startups that raised Series B in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in DACH. On 16 November 2026 that is 67 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 29 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 67 rows: 7 have no round amount, 0 no city and 27 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in DACH whose last round is Series B are on the list?
- 67, in the file dated 16 November 2026. 8 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 67 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.